Please login or register to print this page.


Articles tagged ‘apixaban’

May 28, 2015

NOAC news

The National Institute for Health and Care Excellence (NICE) has issued Final Appraisal Determination (FAD) recommending the NOAC (non-vitamin K oral anticoagulant) apixaban (Eliquis®) as an option for the treatment and prevention of recurrent deep vein thrombosis (DVT) and/or pulmonary embolism (PE) in adults.

read more

March 27, 2015

Apixaban recommended for treating and preventing DVT

Apixaban has been recommended as an option for treating and preventing venous thromboembolism (VTE) in adults in draft guidance1 published recently by the National Institute for Health and Care Excellence (NICE)

read more

December 19, 2014

Lower bleeding risk with apixaban versus VKAs

Apixaban is associated with a lower risk of bleeding than vitamin K antagonists (VKAs), which provides some reassurance regarding its safety, according to the authors of a meta-analysis published recently in the American Journal of Cardiology.1

read more

September 26, 2014

AMPLIFY-EXT shows benefits of extended VTE treatment

Results of a pre-specified secondary analysis of the apixaban phase 3 AMPLIFY-EXT trial (Apixaban after the initial Management of PuLmonary embolIsm and deep vein thrombosis with First-line therapY-EXTended Treatment) were presented during the European Society of Cardiology (ESC) Congress 2014, held recently in Barcelona, Spain.

read more

August 5, 2014

Apixaban versus warfarin and aspirin: results from AVERROES and ARISTOTLE

The efficacy and safety of apixaban compared with aspirin are consistent in subgroups of patients who have previously attempted but failed Vitamin K antagonist (VKA) therapy, irrespective of the reason for discontinuation, according to a study published recently in the European Heart Journal.1

read more

August 5, 2014

Apixaban cost-effective in stroke prevention

Based on randomised trial data, apixaban is a cost-effective alternative to warfarin and aspirin, in vitamin K antagonists (VKA) suitable and VKA unsuitable patients with AF, respectively, according to a recent study.1

read more

June 26, 2014

New oral anticoagulants and bleeding management

As new oral anticoagulants (NOACs) are being prescribed with increasing frequency, and patients are fully anticoagulated, although the risk of intracranial bleeding is reduced, there is still a risk of major haemorrhage. An article by Dr Raza Alikhan (University Hospital of Wales, Cardiff), published in the British Journal of Cardiology,1 provides an understanding of the metabolism and excretion of NOACs, as well as their effects on coagulation tests, which is paramount in the management of patients, particularly in emergency situations.

read more

May 28, 2014

Apixaban can continue during cardioversion

Patients with non valvular atrial fibrillation (NVAF) should remain on apixaban while undergoing cardioversion, according to a recommendation from the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP).1

read more

December 20, 2013

Apixaban unaffected by patient ethnicity

Apixaban was safe and well-tolerated in healthy Chinese subjects, with pharmacokinetics (PK), and pharmacodynamics (PD) predictable and consistent with findings from previous studies in Asian and non-Asian subjects, according to a study1 published recently in Clinical Pharmacology: Advances and Applications.

read more

October 30, 2013

Assay for apixaban plasma concentration

An assay for measuring the circulating blood concentration of the oral Factor Xa inhibitor apixaban is being developed in a joint research agreement between Bristol-Myers Squibb and Diagnostica Stago S.A.S, a privately held company that provides reference tests and instrumentation in haemostasis. No commercial assay is presently available to specifically measure apixaban plasma concentration. The terms of the agreement were not disclosed.

read more

Older articles »

Members Area

Log in or Register now.



Subscribe to our RSS feed


Sign up for our regular email newsletters & be the first to know about fresh articles and site updates.


    None Found


  • ArrhythmiaAlliance
  • Stars
  • Anticoagulation Europe
  • Atrial Fibrillation Association

You are not logged in

You need to be a member to print this page.
Sign up for free membership, or log in.

You are not logged in

You need to be a member to download PDF's.
Sign up for free membership, or log in.